Emerging infectious diseases, vaccines and Guillain-Barré syndrome
- PMID: 34230841
- PMCID: PMC8250889
- DOI: 10.1111/cen3.12644
Emerging infectious diseases, vaccines and Guillain-Barré syndrome
Abstract
The recent outbreak of Zika virus infection increased the incidence of Guillain-Barré syndrome (GBS). Following the first reported case of GBS after Zika virus infection in 2013, there has been a considerable increase in the incidence of GBS in endemic countries, such as French Polynesia and Latin American countries. The association between coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and GBS is another emerging research hotspot. Electrophysiological studies have suggested that GBS patients associated with Zika virus infection or COVID-19 tend to manifest acute inflammatory demyelinating polyneuropathy, rather than acute motor axonal neuropathy (AMAN). Causative autoantibodies, such as anti-ganglioside antibodies in AMAN associated with Campylobacter jejuni infection, have not been identified in GBS associated with these emerging infectious diseases. Nevertheless, recent studies suggested molecular mimicry between these viruses and human proteins related to GBS. Recent studies have shown the efficacy of new vaccines, containing artificial messenger RNA encoding the spike protein of SARS-CoV-2, against COVID-19. These vaccines are now available in many countries and massive vaccination campaigns are currently ongoing. Although there are long-standing concerns about the increased risk of GBS after inoculation of conventional vaccines, the risk of GBS is not considered a legitimate reason to limit administration of currently available vaccines, because the benefits outweigh the risks.
Keywords: Guillain–Barré syndrome; acute inflammatory demyelinating polyneuropathy; acute motor axonal neuropathy; antecedent infection; vaccine.
© 2021 Japanese Society for Neuroimmunology.
Conflict of interest statement
Conflict of interest: The authors declare no conflict of interest.
Figures

Similar articles
-
Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review.Neurol Ther. 2021 Dec;10(2):523-537. doi: 10.1007/s40120-021-00261-4. Epub 2021 Jun 12. Neurol Ther. 2021. PMID: 34117994 Free PMC article. Review.
-
[Zika Virus and Guillain-Barré Syndrome].Brain Nerve. 2018 Feb;70(2):113-120. doi: 10.11477/mf.1416200963. Brain Nerve. 2018. PMID: 29433112 Japanese.
-
Axonal variants of Guillain-Barré syndrome: an update.J Neurol. 2021 Jul;268(7):2402-2419. doi: 10.1007/s00415-020-09742-2. Epub 2020 Mar 5. J Neurol. 2021. PMID: 32140865 Review.
-
Guillain-Barré Syndrome in Mexico: An Updated Review Amid the Coronavirus Disease 2019 ERA.Rev Invest Clin. 2022 May 1;74(3):121-130. doi: 10.24875/RIC.22000006. Rev Invest Clin. 2022. PMID: 35345064 Review.
-
Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.Lancet. 2016 Apr 9;387(10027):1531-1539. doi: 10.1016/S0140-6736(16)00562-6. Epub 2016 Mar 2. Lancet. 2016. PMID: 26948433 Free PMC article.
Cited by
-
The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.Biomedicines. 2024 Jun 4;12(6):1248. doi: 10.3390/biomedicines12061248. Biomedicines. 2024. PMID: 38927455 Free PMC article. Review.
-
Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: A rare pediatric case report and review of literature.Hum Vaccin Immunother. 2023 Aug;19(2):2261199. doi: 10.1080/21645515.2023.2261199. Epub 2023 Sep 27. Hum Vaccin Immunother. 2023. PMID: 37753771 Free PMC article.
-
Microbial lectome versus host glycolipidome: How pathogens exploit glycosphingolipids to invade, dupe or kill.Front Microbiol. 2022 Aug 19;13:958653. doi: 10.3389/fmicb.2022.958653. eCollection 2022. Front Microbiol. 2022. PMID: 36060781 Free PMC article. Review.
-
Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.J Neuroimmunol. 2022 Jun 15;367:577877. doi: 10.1016/j.jneuroim.2022.577877. Epub 2022 Apr 22. J Neuroimmunol. 2022. PMID: 35490444 Free PMC article.
-
Possible association between Guillain-Barré syndrome and SARS-CoV-2 infection in children: A case report and literature review.Exp Ther Med. 2022 May 23;24(1):462. doi: 10.3892/etm.2022.11389. eCollection 2022 Jul. Exp Ther Med. 2022. PMID: 35747147 Free PMC article.
References
-
- Shahrizaila N, Lehmann HC, Kuwabara S. Guillain‐Barré syndrome. Lancet. 2021;397(10280):1214–28. - PubMed
-
- McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain‐Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150–63. - PubMed
-
- Prineas JW. Acute idiopathic polyneuritis. An electron microscope study. Lab Invest. 1972;26(2):133–47. - PubMed
-
- Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, et al Guillain‐Barré syndrome in northern China. the spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118(Pt 3):577–95. - PubMed
-
- Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of miller fisher syndrome. Ann Neurol. 1992;31(6):677–9. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous